Form 8-K - Current report:
SEC Accession No. 0001104659-26-082341
Filing Date
2026-07-10
Accepted
2026-07-09 21:06:20
Documents
12
Period of Report
2026-07-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2620172d1_8k.htm   iXBRL 8-K 25152
2 EXHIBIT 99.1 tm2620172d1_ex99-1.htm EX-99.1 13270
  Complete submission text file 0001104659-26-082341.txt   209258

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20260707.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20260707_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20260707_pre.xml EX-101.PRE 22362
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2620172d1_8k_htm.xml XML 3318
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 261166800
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)